Here is what Mohammed AlQuraishi said in 2020:
CASP14 #s just came out and they’re astounding—DeepMind looks to have solved protein structure prediction. Median GDT_TS went from 68.5 (CASP13) to 92.4!!!! Cf. their 2nd best CASP13 struct scored 92.8 (out of 100). Median RMSD is 2.1Å. I think it's over [0]
and
“I think it’s fair to say this will be very disruptive to the protein-structure-prediction field. I suspect many will leave the field as the core problem has arguably been solved,” he says. “It’s a breakthrough of the first order, certainly one of the most significant scientific results of my lifetime.” [1]
[0] https://twitter.com/MoAlQuraishi/status/1333383634649313280
For instance, the gentlemen who was presented as a skeptic is instead shown to also say it's solved, and in reply to this you say "everyone" is looking at the "wrong" metric, and it allows errors of 8+ atom widths - he notes the median error is 2.1 angstroms, or 2.1 atom widths.
[1] https://blogs.sciencemag.org/pipeline/archives/2019/09/25/wh...
They also have theory groups which try to do structure prediction and drug docking but I don't think those groups get any respect inside the companies any more.
The author acknowledges as much in the preamble, "my mood lifted during the meeting due to the general excitement and quality of discussions, [...] my tribal reflexes gave way to a cooler and more rational assessment".
It's a lack of vision and leadership from pharma labs.
That's probably true, but I don't think Pfizer could have beat DeepMind, even if they had really tried. DeepMind is in a unique position to recruit lots of young deep learning researchers.
Deepmind have at least a few thousand employees, I'm willing to go out on a limb and say that the industry doesn't have "hundreds of thousands" of people working on protein folding alone.
What's important is I think which people they hired, as well as Deepmind-internal infrastructures. You can just walk over to one of the world experts in deep learning and ask them how to address some issue.
In pharma companies they have people who are really smart about drugs and biology, but ML experts would all have to be hired externally, and likely don't represent the top of the field as well as Deepmind does.
I don't know how UK R&D tax works, but most countries allow companies to write off some profits against R&D. Apart from the fact Google wants to do research, having a large center based in the UK probably helps their UK (and formerly EU?) tax position.
> CASP14 #s just came out and they’re astounding—DeepMind looks to have solved protein structure prediction. Median GDT_TS went from 68.5 (CASP13) to 92.4!!!! Cf. their 2nd best CASP13 struct scored 92.8 (out of 100). Median RMSD is 2.1Å. I think it's over
It's a fairly long read, but he goes into a lot more detail as to why the problem isn't yet solved. Interestingly, he also notes that pharma and academia should feel some embarrassment from DeepMind's achievement:
"What is worse than academic groups getting scooped by DeepMind? The fact that the collective powers of Novartis, Pfizer, etc, with their hundreds of thousands (~million?) of employees, let an industrial lab that is a complete outsider to the field, with virtually no prior molecular sciences experience, come in and thoroughly beat them on a problem that is, quite frankly, of far greater importance to pharmaceuticals than it is to Alphabet. It is an indictment of the laughable “basic research” groups of these companies, which pay lip service to fundamental science but focus myopically on target-driven research that they managed to so badly embarrass themselves in this episode."
[1] https://moalquraishi.wordpress.com/2018/12/09/alphafold-casp...
(Edited to clarify that the blog post was not recent.)